Sickle Cell DiseasePipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Purchase Option

$ 4400
$ 4000
$ 6000

Sickle-cell diseases (SCD) are types of blood disorders which are usually inherited genetically. One of the common types of SCDs is the sickle-cell anemia or SCA. It essentially gives rise to an irregularity in hemoglobin, the protein that carries oxygen in the blood. Hemoglobin is found typically in the red blood cells of the body. As a result, a sickle-like shaped cell is formed under certain conditions. Tribulations in sickle cell disease usually start to take shape at a very early age (within the first year of birth). This might lead to various health problems including pain attacks also known as the sickle-cell crisis, swelling in the limbs, microbial infections, and in certain cases, stroke. SCD is diagnosed by blood tests and Hb electrophoresis. Hydroxyurea is the only FDA approved drug for treatment of Sickle-cell diseases.

 Key Developments:

  • In December 2017, Novartis Pharmaceuticals released results of post hoc subgroup analysis of the Phase II SUSTAIN study of crizanlizumaban investigational humanized anti-P-selectin monoclonal antibody determined that crizanlizumab delayed the time to first sickle cell pain crisis in patients vs. placebo in key subgroups of adult patients with sickle cell disease
  • In February 2017, bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease.

Sickle Cell Disease Pipeline Drugs Assessment Dynamics

Sickle Cell DiseaseDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Sickle Cell Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Sickle Cell Diseasedisease pipeline drugs development. This report studies the dynamics of the Sickle Cell DiseaseDisease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Sickle Cell Diseasedisease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Sickle Cell Disease Pipeline Drugs Assessment Segmentation

By Trial Phase
  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

 

 

By Drugs
  • Prasugrel
  • Sevuparin
  • L-Citruline
  • Ticagrelor
  • Docosahexaenoic Acid
  • sapropterindihydrochloride
  • Treprostinil
  • Deferiprone
  • Others
By Type of Disease
  • Sickle cell anemia
  • Sickle cell hemoglobin C disease
  • Sickle cell thalassemia disease
By Route of Administration
  • Oral
  • Parenteral

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Sickle Cell Disease Pipeline Drugs Assessment Market Introduction 
2.1.Global Sickle Cell Disease Pipeline Drugs Assessment Market  - Taxonomy
2.2.Global Sickle Cell Disease Pipeline Drugs Assessment Market  - Definitions
2.2.1.Trial Phase
2.2.2.Drugs
2.2.3.Type of Disease
2.2.4.Route of Administration
3. Global Sickle Cell Disease Pipeline Drugs Assessment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Sickle Cell Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Sickle Cell Disease Pipeline Drugs Assessment Market  By Trial Phase, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Preclinical Trials
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Phase 1
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Phase 2
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Phase 3
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Phase 4
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6. Global Sickle Cell Disease Pipeline Drugs Assessment Market  By Drugs, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Prasugrel
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Sevuparin
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. L-Citruline
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Ticagrelor
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Docosahexaenoic Acid
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. sapropterindihydrochloride
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Treprostinil
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
6.8. Deferiprone
6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.8.3. Market Opportunity Analysis 
6.9. Others
6.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.9.3. Market Opportunity Analysis 
7. Global Sickle Cell Disease Pipeline Drugs Assessment Market  By Type of Disease, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Sickle cell anemia
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Sickle cell hemoglobin C disease
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Sickle cell thalassemia disease
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Sickle Cell Disease Pipeline Drugs Assessment Market  By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Oral
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Parenteral
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
9. Competition Landscape
9.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
9.2.1.Eli Lilly and Company
9.2.2.NKT Therapeutics
9.2.3.AstraZeneca
9.2.4.Novartis
9.2.5.bluebird bio
9.2.6.BioMarin Pharmaceutical
9.2.7.Imara, Inc.
9.2.8.Mast Therapeutics, Inc.
9.2.9.Pfizer
9.2.10.Sanofi
9.2.11.Endo Pharmaceuticals
10. Research Methodology 
11. Appendix and Abbreviations 
  • Eli Lilly and Company
  • NKT Therapeutics
  • AstraZeneca
  • Novartis
  • bluebird bio
  • BioMarin Pharmaceutical
  • Imara, Inc.
  • Mast Therapeutics, Inc.
  • Pfizer
  • Sanofi
  • Endo Pharmaceuticals

Adjacent Markets